The In vitro Impact of Moxifloxacin and Gatifloxacin Concentration (0.5% vs 0.3%) and the Addition of Benzalkonium Chloride on Antibacterial Efficacy

American Journal of Ophthalmology

Volumn 142, Issue 5, 2006, Pages

  Kowalski, Regis P ^a,b   Kowalski, Brittany R ^b   Romanowski, Eric G ^b   Mah, Francis S ^b   Thompson, Paul P ^b   Gordon, Y Jerold ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b University of Pittsburgh School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; GATIFLOXACIN; MOXIFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG EFFICACY; ENDOPHTHALMITIS; IN VITRO STUDY; KERATITIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 33750968802     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2006.06.006     Document Type: Article

References (11)

1. Mather R., Karenchak L.M., Romanowski E.G., and Kowalski R.P. Fourth-generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133 (2002) 463-466
2. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., Romanowski E.G., et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136 (2003) 500-505
3. Kowalski R.P., Yates K.A., Romanowski E.G., et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration (MIC) data. Ophthalmology 112 (2005) 1987-1991
4. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobials susceptibility tests for bacteria that grow aerobically, ed. 4. Approved standard vol. 20 (2003), National Committee for Clinical Laboratory Standards, Villanova, PA document M7-A6, No. 2
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement vol. 24 (2005), Clinical and Laboratory Standards Institute, Wayne, PA document M100-S15, No. 1
6. Kowalski R.P., Pandya A.N., Karenchak L.M., et al. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology 108 (2001) 1826-1829
7. Kim D.H., Stark W.J., O'Brien T.P., and Dick J.D. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology 112 (2005) 1992-1996
8. Pillai S.K., Moellering R.C., and Eliopoulos G.M. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 5th ed. (2005), Lippincott Williams & Wilkins, Philadelphia, Pennsylvania 365-440
9. Holm S.E., Tornqvist I.O., and Cars O. Paradoxical effects of antibiotics. Scand J Infect Dis Suppl 74 (1990) 113-117
10. Lambert R.J. Comparative analysis of antibiotic and antimicrobial biocide susceptibility data in clinical isolates of methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa between 1989 and 2000. J Appl Microbiol 97 (2004) 699-711
11. Solomon R., Donnenfeld E.D., Perry H.D., et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 112 (2005) 466-469